欧洲委员会核准Catumaxomab,第一种治疗严重癌症并发症的药物。 European Commission approves Catumaxomab, first drug for treating severe cancer complication.

欧盟委员会批准了Lindis Biotech和Pharmanovia公司新药Catumaxomab作为治疗恶性炎的首种药物, 这是一种晚期癌症的严重并发症, The European Commission has approved Catumaxomab, a new drug by Lindis Biotech and Pharmanovia, as the first treatment for malignant ascites, a severe complication of advanced cancer causing fluid buildup in the abdomen. 根据许可证协议 药剂师将带领药物的市场 在整个欧洲发起。 Under a licensing deal, Pharmanovia will lead the drug's market launch across Europe. Catumaxomab的目标是通过针对肿瘤细胞和增强免疫系统来改善患者的生活质量。 Catumaxomab aims to improve patients' quality of life by targeting tumor cells and boosting the immune system.